Goiter classification: Difference between revisions
No edit summary |
|||
Line 39: | Line 39: | ||
**'''Epithelial tumors''' | **'''Epithelial tumors''' | ||
***Benign | ***Benign | ||
****Follicular adenoma | ****''Follicular adenoma'' | ||
****Others | ****''Others'' | ||
***Malignant | ***Malignant | ||
****Follicular carcinoma | ****''Follicular carcinoma'' | ||
****Papillary carcinoma | ****''Papillary carcinoma'' | ||
****Medullary carcinoma | ****''Medullary carcinoma'' | ||
****Undifferentiated (anaplastic) carcinoma | ****''Undifferentiated (anaplastic) carcinoma'' | ||
****Others | ****''Others'' | ||
**'''Nonepithelial tumors''' | **'''Nonepithelial tumors''' | ||
***Benign | ***''Benign'' | ||
***Malignant | ***''Malignant'' | ||
**'''Malignant lymphomas''' | **'''Malignant lymphomas''' | ||
**'''Miscellaneous tumors''' | **'''Miscellaneous tumors''' | ||
Line 55: | Line 55: | ||
**'''Unclassified tumors''' | **'''Unclassified tumors''' | ||
**'''Tumor-like lesions''' | **'''Tumor-like lesions''' | ||
Revision as of 18:30, 8 September 2017
Goiter Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Goiter classification On the Web |
American Roentgen Ray Society Images of Goiter classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Classification
- In 1974, an international committee of thyroid pathologists published the first WHO histological classification of thyroid tumours which had served as a basis for various clinical, pathological, and epidemiological studies. [1]
- WHO Histological Classification of Thyroid Tumors, Second edition (1988) [1]
- Epithelial tumors
- Benign
- Follicular adenoma
- Others
- Malignant
- Follicular carcinoma
- Papillary carcinoma
- Medullary carcinoma
- Undifferentiated (anaplastic) carcinoma
- Others
- Benign
- Nonepithelial tumors
- Benign
- Malignant
- Malignant lymphomas
- Miscellaneous tumors
- Secondary tumors
- Unclassified tumors
- Tumor-like lesions
- Epithelial tumors
- There is no established system for the classification of [disease name].
OR
- [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [Group1]
- [Group2]
- [Group3]
- [Group4]
OR
- [Disease name] may be classified into [large number > 6] subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
- [Disease name] may be classified into several subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
OR
- Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
- If the staging system involves specific and characteristic findings and features:
- According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
- The staging of [malignancy name] is based on the [staging system].
OR
- There is no established system for the staging of [malignancy name].